射频消融联合分子靶向药物(EGFR-TKI)治疗老年非小细胞肺癌的临床疗效

Clinical Efficacy of Ablation Combined with Gene Targeting Therapy(EGFR-TKI) for Elderly Patients with Non-small Cell Lung Cancer

目的探究消融联合化疗和靶向药物治疗老年非小细胞肺癌的临床疗效。方法选取108例非小细胞肺癌老年患者为研究对象,采用随机数表法将其分为观察组和对照组,各54例。对照组患者给予化疗和靶向药物治疗,观察组患者在对照组患者的基础上联合肿瘤消融治疗。对比2组患者的临床疗效、生活质量和不良反应发生情况。结果观察组的临床总有效率为68.5%,明显高于对照组患者的37.1%,差异具有统计学意义(P<0.05)。生活质量各项评分的比较中观察组均显著优于对照组,差异具有统计学意义(P<0.05)。观察组疼痛、发热的发生率均显著高于对照组(P<0.05),但腹泻和皮疹的发生率差异均无统计学意义(P>0.05)。结论靶向药物和消融联合化疗治疗老年非小细胞肺癌能够更好地抑制肿瘤的生长,提高临床疗效和改善患者的生活质量,可以在临床上进一步推广和使用。

Objective To explore the clinical efficacy of ablation combined with chemotherapy and targeted drug therapy for elderly patients with non-small cell lung cancer .Methods 108 elderly patients with non-small cell lung cancer ,according to random number table ,were divided the observation group and the control group ,54 cases in each group .The control group were given chemotherapy and targeted drug therapy , the observation group received joint tumor ablation on the basis of the control group.Clinical efficacy,quality of life and adverse events were compared between the 2 groups.Results Clinical total effective rate of the observation group was 68.5%,which were significantly higher than the control group of 37.1%,there had statistical difference （P〈0.05）.The observation group were significantly better than the control group in quality of life ,there had statistical difference （P〈0.05）.The incidence of pain,fever were significantly higher than the control group ,the difference has statistical significance （P〈0.05）.The incidence of diarrhea and skin rash had no statistically significant difference between the 2 groups （P〉0.05）.Conclusion Targeted drugs and ablation combined with chemotherapy for elderly patients with non -small cell lung cancer can inhibit tumor growth ,improve the clinical efficacy and improve the quality of life of patients ,it is worthy of further pro-motion in clinical practice .